BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

741 related articles for article (PubMed ID: 25531258)

  • 1. Epigenetic mechanisms of breast cancer: an update of the current knowledge.
    Karsli-Ceppioglu S; Dagdemir A; Judes G; Ngollo M; Penault-Llorca F; Pajon A; Bignon YJ; Bernard-Gallon D
    Epigenomics; 2014; 6(6):651-64. PubMed ID: 25531258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
    Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
    Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic reprogramming in breast cancer: from new targets to new therapies.
    Katz TA; Huang Y; Davidson NE; Jankowitz RC
    Ann Med; 2014 Sep; 46(6):397-408. PubMed ID: 25058177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic inactivation of DNA repair in breast cancer.
    Nowsheen S; Aziz K; Tran PT; Gorgoulis VG; Yang ES; Georgakilas AG
    Cancer Lett; 2014 Jan; 342(2):213-22. PubMed ID: 22634493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.
    Walsh L; Gallagher WM; O'Connor DP; Ní Chonghaile T
    Expert Rev Mol Diagn; 2016; 16(5):541-51. PubMed ID: 26895288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetics in prostate cancer: biologic and clinical relevance.
    Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF
    Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer.
    Oh S; Ko JY; Oh C; Yoo KH
    Adv Exp Med Biol; 2017; 1026():287-313. PubMed ID: 29282690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA demethylating agents and epigenetic therapy of cancer.
    Mani S; Herceg Z
    Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative epigenetic analyses reveal distinct patterns of oncogenic pathways activation in breast cancer subtypes.
    Li Y; Li S; Chen J; Shao T; Jiang C; Wang Y; Chen H; Xu J; Li X
    Hum Mol Genet; 2014 Oct; 23(20):5378-93. PubMed ID: 24871326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic regulation and cancer (review).
    Chen QW; Zhu XY; Li YY; Meng ZQ
    Oncol Rep; 2014 Feb; 31(2):523-32. PubMed ID: 24337819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review-Epigenetic therapy for cancer.
    Saleem M; Abbas K; Manan M; Ijaz H; Ahmed B; Ali M; Hanif M; Farooqi AA; Qadir MI
    Pak J Pharm Sci; 2015 May; 28(3):1023-32. PubMed ID: 26004710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic modifications in prostate cancer.
    Ngollo M; Dagdemir A; Karsli-Ceppioglu S; Judes G; Pajon A; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon DJ
    Epigenomics; 2014; 6(4):415-26. PubMed ID: 25333850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and epigenetic aspects of breast cancer progression and therapy.
    Byler S; Goldgar S; Heerboth S; Leary M; Housman G; Moulton K; Sarkar S
    Anticancer Res; 2014 Mar; 34(3):1071-7. PubMed ID: 24596345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic mechanisms regulate the prostaglandin E receptor 2 in breast cancer.
    To SQ; Takagi K; Miki Y; Suzuki K; Abe E; Yang Y; Sasano H; Simpson ER; Knower KC; Clyne CD
    J Steroid Biochem Mol Biol; 2012 Nov; 132(3-5):331-8. PubMed ID: 22929011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
    Shin H; Kim JH; Lee YS; Lee YC
    Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation and histone modifications in breast cancer.
    Dumitrescu RG
    Methods Mol Biol; 2012; 863():35-45. PubMed ID: 22359286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic regulation as a new target for breast cancer therapy.
    Stearns V; Zhou Q; Davidson NE
    Cancer Invest; 2007 Dec; 25(8):659-65. PubMed ID: 18058459
    [No Abstract]   [Full Text] [Related]  

  • 20. Epigenetic gene regulation in cancer.
    Ballestar E; Esteller M
    Adv Genet; 2008; 61():247-67. PubMed ID: 18282509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.